Shannon Kratzer
Nurse Practitioner · Newburgh, INNPI 1871821629
Payments from drug & device makers
What this record shows
46 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 54.2% of the total. Reporting peaked in 2021 at $7,594 and has fallen 82.3% since, to $1,348 in 2025. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$6K
- AbbVie$1K
- Pfizer$589
- Amgen$468
- GSK$466
- Novo Nordisk$325
- plus $3K from 40 others
What the payments were for
- Speaking & faculty fees$6,13552%
- Food & beverage$5,77448%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$6,259
- AIRSUPRA$118
- BREZTRI$118
- FARXIGA$118
How this compares
$11,909 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $89,412 |
| OzempicSemaglutide | 67 | $79,989 |
| EliquisApixaban | 76 | $63,778 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $50,740 |
| JanuviaSitagliptin Phosphate | 45 | $44,626 |
| JardianceEmpagliflozin | 48 | $37,804 |
| BelsomraSuvorexant | 44 | $22,466 |
| VraylarCariprazine Hcl | 14 | $22,182 |
| LinzessLinaclotide | 30 | $22,019 |
| Emgality PenGalcanezumab-Gnlm | 26 | $20,190 |
| FarxigaDapagliflozin Propanediol | 24 | $19,793 |
| GemtesaVibegron | 18 | $18,208 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,713 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $13,275 |
| Ondansetron Hcl | 45 | $12,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $138 | $89,41282 claims |
| Novo NordiskOzempic | $325 | $79,98967 claims |
| MerckJanuvia, Belsomra, Dulera | $202 | $70,938100 claims |
| PfizerEliquis | $589 | $63,77876 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $36 | $53,19775 claims |
| GSKTrelegy Ellipta | $466 | $50,74078 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,082 | $46,57161 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $219 | $33,50546 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $49 | $18,20818 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $11,29717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Newburgh
- Kimberly BurkNewburgh$27K
- Elise SchuttNewburgh$10K
- Jordyn NovsekNewburgh$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.